So this study doesn't show any of those things that Mike is claiming. It references other studies that have indicated some promise for ivermectin as a broad-spectrum antiviral, but Mike is really overselling this thing. Also, as it relates to dengue, the study literally says, quote, ivermectin was the focus of a recent phase 3 clinical trial in dengue patients in Thailand, in which a single daily dose was found to be safe, but not produce any clinical benefit.